In Interview, Spyryx CEO Talks of Potential of CF Treatment Now Entering Clinical Testing
A preclinical study using animal models of cystic fibrosis (CF) showed that SPX-101, a treatment being developed by Spyryx Biosciences, effectively cleared lung mucus in the animals, regardless of the presence of genetic mutations that promote the development of the disease. Results of this study were presented by John Taylor, Spyryx’s president…